GlassScriptPhysician profile
John C Lalonde
NPI 1245274455
$14,435.89
in general payments reported to CMS, 2019-2025
61 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $1,911 · 2021: $2,129 · 2022: $2,282 · 2023: $2,058 · 2024: $2,142 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,164.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,263.75 | 2019-2025 | Descovy, Biktarvy |
| Astrazeneca Pharmaceuticals LP | $1,743.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Viiv Healthcare Company | $1,729.89 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Novo Nordisk INC | $1,029.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $889.56 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $756.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $648.24 | 2019-2025 | |
| Abbott Laboratories | $535.73 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $420.90 | 2020-2025 | Pifeltro, Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.40 | 2019-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $329.20 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $314.99 | 2019-2021 | |
| Pfizer INC. | $311.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $302.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $236.48 | 2021-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lalonde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.